Key Highlights
- Shares of Soleno Therapeutics (SLNO) jumped more than 30% in Monday’s premarket session following acquisition reports
- Neurocrine Biosciences (NBIX) is reportedly nearing a deal to purchase Soleno valued at over $2.5 billion
- The proposed transaction could price SLNO shares in the low-to-mid $50 range
- According to the Financial Times, an agreement may be reached as early as Monday, April 6
- Shares of Neurocrine declined 0.4% in premarket activity following the news
After struggling through early 2026 with a decline of approximately 14% year-to-date, Soleno Therapeutics experienced a dramatic reversal Monday morning.
Soleno Therapeutics, Inc., SLNO
According to a Financial Times report, Neurocrine Biosciences has entered late-stage negotiations to acquire the rare disease-focused biotechnology company in a transaction exceeding $2.5 billion. News of the potential buyout propelled SLNO shares more than 30% higher in premarket hours.
The proposed acquisition would establish Soleno’s valuation in the low-to-mid $50s per share. Negotiations are advancing at a rapid pace, with the FT indicating that parties could finalize terms as soon as Monday.
Soleno’s primary commercial product is Vykat XR, a treatment the company introduced last year targeting hyperphagia — a debilitating condition associated with Prader-Willi syndrome. This condition triggers uncontrollable, chronic hunger that can result in severe health complications such as gastric rupture, asphyxiation risks, morbid obesity, and heart disease.
Prader-Willi syndrome represents a rare genetic condition, affecting approximately one in 15,000 newborns worldwide. Vykat XR holds the distinction of being the first FDA-approved therapy specifically designed to address hunger-related manifestations of this syndrome.
Industry analysts have projected that Vykat XR could achieve peak yearly revenues approaching $2.3 billion — a forecast that has evidently attracted significant interest from Neurocrine.
Neurocrine’s Strategic Push Into Rare Diseases
Neurocrine presently maintains a market capitalization of approximately $13.21 billion. The company’s existing product lineup features Ingrezza, a treatment for involuntary movement disorders associated with Huntington’s disease, alongside multiple other commercial products and pipeline candidates.
Acquiring Vykat XR would establish Neurocrine’s presence in the rare disease and orphan pharmaceutical sector, where companies typically benefit from favorable pricing dynamics and reduced competitive pressure.
Shares of Neurocrine fell 0.4% during Monday’s premarket session. This modest decline represents a common market response when acquiring companies announce major deals — shareholders factor in the premium being offered.
Understanding SLNO’s Recent Performance
Despite Monday’s dramatic surge, SLNO had declined roughly 14% during 2026 prior to this week. The stock had faced headwinds even as analysts maintained bullish projections regarding Vykat XR’s revenue prospects.
According to TipRanks data, SLNO carries a Strong Buy rating based on consensus from 11 covering analysts. The mean price objective stands at $101.09, while the most optimistic target reaches $125.
If finalized at the reported valuation of low-to-mid $50s per share, the transaction would fall considerably short of these analyst projections — although it would still deliver a meaningful premium compared to SLNO’s recent trading levels.
The Financial Times article referenced unnamed sources with knowledge of the discussions, emphasizing that negotiations are advancing smoothly and quickly approaching a potential final agreement.
